Parabilis, a biotech firm focused on antibody-Helicon conjugates, filed for an initial public offering a day after inking a strategic research collaboration with Regeneron Pharmaceuticals. The partnership is valued at up to $2.3 billion, covering an initial five drug candidates aimed at challenging, historically undruggable targets.
Under the deal, Regeneron will purchase roughly $75 million of Parabilis common stock in a concurrent private placement, at 90% of the IPO price per share. The collaboration focuses on a new class of antibody-drug conjugates designed to overcome biological barriers that have resisted traditional targeting.
The IPO filing follows a period of heightened biotech investment, particularly in novel therapeutic platforms. Parabilis did not disclose the number of shares or expected price range in its initial filing, though the Regeneron tie-up adds significant validation.
Investors may view the partnership as a strong endorsement of Parabilis's platform, but the company remains pre-revenue and faces typical clinical development risks. The IPO proceeds will likely fund early-stage trials for its lead candidates.
A key risk is that the collaboration's total $2.3 billion value depends on milestone achievements, most of which are years away. Regeneron's equity stake also gives it influence over Parabilis's strategic direction.